Trichomoniasis is the most common nonviral STI and is associated with serious health risks and reproductive morbidity in women.2
Different patients.
One effective solution.
Now with a NEW indication for trichomoniasis
SOLOSEC demonstrated a cure rate of 92.2% for trichomoniasis in women in the phase-3 trial.3
ACOG and CDC no longer recommend single dose metronidazole to treat trichomoniasis in women.2,4
SOLOSEC is approved to treat partners of trichomoniasis patients with the same single dose each at the same time.1
Take the Trich Challenge
Test your knowledge of trichomoniasis guidelines and clinical management principles based on the latest epidemiological and clinical data.
Trichomoniasis is the most common nonviral STI and is associated with serious health risks and reproductive morbidity in women.2
Different patients. One effective solution.


Now with a NEW indication for trichomoniasis
SOLOSEC demonstrated a cure rate of 92.2% for trichomoniasis in women in the phase-3 trial.3
ACOG and CDC no longer recommend single dose metronidazole to treat trichomoniasis in women.2,4
SOLOSEC is approved to treat partners of trichomoniasis patients with the same single dose each at the same time.1
Take the Trich Challenge
Test your knowledge of trichomoniasis guidelines and clinical management principles based on the latest epidemiological and clinical data.
References:
References: 1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2021. 2. Workowski KA, Bachmann LH, Chan PA, et al. CDC Sexually Transmitted Diseases Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(RR-04):1-192. 3. Muzny CA, Schwebke JR, Nyirjesy P, et al. Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study. Clin Infect Dis 2021. 4. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists, Number 215. Obstet Gynecol 2020:135(1):e1-e17.